



CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT: Daum et al.

TITLE: THERAPY VIA TARGETED DELIVERY OF NANOSCALE PARTICLES

SERIAL NO.: 10/696,339

ATTORNEY REF: 126381.1301

DATE OF DEPOSIT: January 13, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT TOGETHER WITH THE DOCUMENTS CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

1. Information Disclosure Statement with cited references;
2. Certificate of Mailing;
3. Postcard



Attorney Docket No.: 126381.1301

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DAUM et al.

Serial No. 10/696,339

Filed: October 28, 2003

For: THERAPY VIA TARGETED DELIVERY OF NANOSCALE
PARTICLES

:
:
: Group Art Unit: Not yet assigned
: Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink that reads "Raymond A. Miller". The signature is written in a cursive, flowing style.

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: January 12, 2004



Substitution for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known					
				Application Number		10/696,339			
				Filing Date		October 28, 2003			
				First Named Inventor		Daum et al.			
				Group Art Unit		Not yet assigned			
Examiner Name		Not yet assigned		Attorney Docket Number		126381.1301			
Sheet	1	of 2							
U.S. PATENT DOCUMENTS									
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number	Kind Code (if known)						
FOREIGN PATENT DOCUMENTS									
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T
		Office	Number	Kind Code (if known)					
	BA	WO	03 043583		Law et al.	11-20-2002			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.							
	CA	Boyd, R, "Radisotopes in Medicine" Nuclear Issues Briefing Paper 26; http://www.vic.com.au/nipz6							
	CB	Marx, J, "A Boost of Tumor Starvation", Science, 25 July 2003, Vol 301, 452-454							
	CC	Kling, J, "Ceramic-Based Nanoparticles: Drug Carriers for Photodynamic Therapy", www.chemistry.org , 10/24/2003							
	CD	Keating, M. J., "Management Strategies for Chronic Lymphocytic Leukemia", www.medscape.com , June 10, 2003							
	CE	Hawkins, F, "Vasopermeation Enhancement Agent Technology Highlighted", www.peregrineinc.com , 10/22/2003							
	CF	Moskowitz, B, "Magnetotactic Bacteria", Rev. Geophys., Vol 33, Suppl., 10/22/2003, www.agu.org/revgeophys/moskow01/node1.html							
	CG	"Magnetococcus MS-1 Genome Project", 10/22/2003							
	CH	"Magnetospirillum Magnetotacticum", 10/22/2003, www.genome.jgi-psf.org/draft_microbes/magma.home.html							
	CI	Menez R, "Crystal Structure of a hydrophobic immunodominant antigenic site on hepatitis C virus core protein complexed monoclonal antibody", J. Immunol, Vol 170, 2003 Feb 15, 1917-19224							
	CJ	Jayson G, "Molecular Imaging and Biological Evaluation of HuMV833 anti-VEGF antibody: Implications for Trial Design of Antiangiogenic Antibodies", J o t National Cancer Institute, Vol 94, No 19, 10/2/2002, 1484-1493							
	CK	Dormann J, "Magnetic Relaxation in Fine-Particle Systems", Adv. I. Chem. Phys., Vol XCVIII, ISBN 0-471-26285-X, 1997, 283-494							
	CL	"The Internet Drug Database"							
	CM	Stetman's Electronic Medical Dictionary, Version 5, www.stetmans.com							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.